Sensei Biotherapeutics (Sensei Biotherapeutics) Interest Expense : $-0.13 Mil (TTM As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Sensei Biotherapeutics Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Sensei Biotherapeutics's interest expense for the three months ended in Mar. 2024 was $ -0.03 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.13 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Sensei Biotherapeutics's Operating Income for the three months ended in Mar. 2024 was $ -8.73 Mil. Sensei Biotherapeutics's Interest Expense for the three months ended in Mar. 2024 was $ -0.03 Mil. Sensei Biotherapeutics did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Sensei Biotherapeutics Interest Expense Historical Data

The historical data trend for Sensei Biotherapeutics's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sensei Biotherapeutics Interest Expense Chart

Sensei Biotherapeutics Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-2.26

-1.69

-0.67

-0.22

-0.14

Sensei Biotherapeutics Quarterly Data
	Dec18	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Interest Expense	Get a 7-Day Free Trial															-0.04	-0.04	-0.03	-0.03	-0.03

Sensei Biotherapeutics Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.13 Mil.

Sensei Biotherapeutics (NAS:SNSE) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Sensei Biotherapeutics's Interest Expense for the three months ended in Mar. 2024 was $-0.03 Mil. Its Operating Income for the three months ended in Mar. 2024 was $-8.73 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2024 was $3.16 Mil.

Sensei Biotherapeutics's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as

Sensei Biotherapeutics did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Sensei Biotherapeutics (Sensei Biotherapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sensei Biotherapeutics Inc (NAS:SNSE) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

407:Germany 407:Germany

Address

1405 Research Boulevard, Suite 710, Boston, MA, USA, 02210

Website

https://www.senseibio.com

Sensei Biotherapeutics Inc is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. The company currently has three investigational products. 1) SNS-101 is a conditionally active monoclonal antibody targeting the immune checkpoint VISTA (V-domain Ig suppressor of T-cell activation): 2) SNS-102 is a conditionally active monoclonal antibody targeting VSIG4 (V-Set and Immunoglobulin Domain Containing 4), an immune checkpoint often expressed on macrophages: 3) SNS-103 is a conditionally active monoclonal antibody targeting ENTPDase1 (ecto-nucleoside triphosphate diphosphohydrolase-1), also known as CD39.

Executives

Stephanie Krebs	officer: Chief Business Officer	C/O SENSEI BIOTHERAPEUTICS, INC., 1405 RESEARCH BLVD, SUITE 125, ROCKVILLE MD 20850
John Celebi	director, officer: President & CEO	SENSEI BIOTHERAPEUTICS, INC., 1405 RESEARCH BLVD., STE. 125, ROCKVILLE MD 20850
James Peyer	director, 10 percent owner	C/O SENSEI BIOTHERAPEUTICS, INC., 1405 RESEARCH BLVD., STE. 125, ROCKVILLE MD 20850
Cambrian Biopharma Inc	10 percent owner, other: See Remarks	228 PARK AVENUE S., #66643, NEW YORK NY 10003
Apeiron Investment Group Ltd.	10 percent owner	BLOCK A, APT.12, IL-PIAZZETTA, TOWER ROAD, SLIEMA O1 SLM1605
Presight Sensei Co-invest Fund, L.p.	other: See Explanation of Responses	340 S. LEMON AVE., # 3391, WALNUT CA 91789
Van Der Horst Edward	officer: Chief Scientific Officer	C/O SENSEI BIOTHERAPEUTICS, INC., 451 D STREET, SUITE 710, BOSTON MA 02210
Presight Co-invest Management, L.l.c.	10 percent owner	340 SOUTH LEMON AVENUE #3391, WALNUT CA 91789
Christian Angermayer	10 percent owner	BLOCK A, APT.12, IL-PIAZZETTA, TOWER ROAD, SLIEMA O1 SLM1605
Patrick Stephen Gallagher	officer: Chief Business Officer	66 HAROLD ST, BOSTON MA 02119
William R Ringo	director
Thomas G Ricks	director	H&S VENTURES LLC, 2101 EAST COAST HWY - 3RD FLOOR, CORONA DEL MAR CA 92625
Robert Hamilton Pierce	officer: Chief Scientific Officer	C/O SENSEI BIOTHERAPEUTICS, INC., 1405 RESEARCH DR.., STE. 125, ROCKVILLE MD 20850
Kristian Humer	director	C/O VIRIDIAN THERAPEUTICS, INC., 6200 LOOKOUT ROAD, BOULDER CO 80301
Jessie English	director	C/O SENSEI BIOTHERAPEUTICS, INC., 1405 RESEARCH DR., STE. 125, ROCKVILLE MD 20850